ライフサイエンスコーパス: extramedullary

1 Myeloid sarcomas are extramedullary accumulations of immature myeloid cells t

2 mplete responses occurred in 4 patients with extramedullary acute myeloid leukemia and 1 patient with

3 tologic subtypes of these cancers, including extramedullary acute myeloid leukemia.

4 DNA from extramedullary AML relapse after HSCT was compared with

5 e loss of graft-versus-leukemia response and extramedullary AML relapse in tissue with reduced immuno

6 hypothesized that this mechanism applies to extramedullary AML relapse which occurs frequently after

7 best characterized in the mouse, where it is extramedullary and utilizes progenitors and signals that

8 review inflammation's effects on central and extramedullary B lymphopoiesis and discuss the potential

9 The patient with extramedullary blastic disease achieved complete respons

10 onic phase; and 1 had a complete response in extramedullary blastic disease).

11 cells into BM, an in vivo model of humanized extramedullary BM (EXM-BM) was developed in NOD/SCID/IL-

12 Here, we describe the development of extramedullary bone and bone marrow using human mesenchy

13 ulation of the bone marrow microenvironment: Extramedullary bone marrow in which hypoxia-inducible fa

14 al and leukemic cells engraft into the human extramedullary bone marrow.

15 ctively; P < .001), and higher likelihood of extramedullary disease (16% v 5%, respectively; P = .013

16 Purpose Extramedullary disease (EMD) at diagnosis in patients wi

17 ved EFS (P = .02), whereas grade 4 aGVHD and extramedullary disease at diagnosis led to inferior OS.

18 Extramedullary disease at diagnosis was an independent p

19 ytogenetic abnormalities, or the presence of extramedullary disease at diagnosis.

20 Extramedullary disease is associated with adverse progno

21 Extramedullary disease is typically an aggressive, poorl

22 well as transformation from myeloma to overt extramedullary disease such as sPCL.

23 recurrent disease after therapy, especially extramedullary disease, is a poor prognostic factor.

24 ty, with or without imaging-based absence of extramedullary disease, to allow uniform reporting withi

25 Another 4 (25%) of 16 patients had focal extramedullary disease.

26 ansplantation and pretransplant diagnosis of extramedullary disease.

27 ration, focal bone lesions, and soft-tissue (extramedullary) disease.

28 Extramedullary (EM) manifestations of acute leukemia inc

29 after bone marrow (BM) relapse and isolated extramedullary (EM) relapse for 347 patients with SR-ALL

30 cellular bone marrow (BM), splenomegaly with extramedullary erythropoiesis and erythropoietin-indepen

31 tosis that was partially compensated by avid extramedullary erythropoiesis at all erythroid stages in

32 th elevated bacterial burdens, implying that extramedullary erythropoiesis benefits the host.

33 y, elevated erythropoietin (EPO) levels, and extramedullary erythropoiesis in a process independent o

34 ens of infected mice despite the presence of extramedullary erythropoiesis in this tissue.

35 ocytes in the peripheral blood and extensive extramedullary erythropoiesis indicated that the Rb-/- e

36 roid and erythroid tissues, including during extramedullary erythropoiesis induced by n-acetylphenylh

37 In an attempt to overcome this anemia, extramedullary erythropoiesis was activated.

38 emolytic anemia with compensatory marrow and extramedullary erythropoiesis, abundant circulating sick

39 fever with splenomegaly, microcytic anemia, extramedullary erythropoiesis, and increased hemophagocy

40 a, hemolytic anemia with reticulocytosis and extramedullary erythropoiesis, and, notably, the charact

41 R3K5A) mice were found to have splenomegaly, extramedullary erythropoiesis, granulocytosis and thromb

42 vere anemia despite the presence of enhanced extramedullary erythropoiesis.

43 se in Hb, and diminished reticulocytosis and extramedullary erythropoiesis.

44 ases in hemoglobin (Hb) level and diminished extramedullary erythropoiesis.

45 This disease, which was characterized by extramedullary erythropoietin-independent erythropoiesis

46 vis was requested to enable exclusion of any extramedullary extension of leukemia.

47 Extramedullary (extraosseus) PCT are rare spontaneous ne

48 d SCID mice developed osteomyelofibrosis and extramedullary/extrasplenal hemopoiesis.

49 rom the bone marrow to the spleen and induce extramedullary haematopoiesis (EMH).

50 a link between the IL17 cytokine family and extramedullary haematopoiesis, and suggests a previously

51 This report describes an unusual extramedullary hematologic malignancy in an 18-month-old

52 ts and platelet counts, and markedly reduced extramedullary hematopoeisis and bone marrow fibrosis.

53 characterized by splenomegaly, leukocytosis, extramedullary hematopoiesis (EMH) in spleen and liver w

54 Extramedullary hematopoiesis (EMH) is induced during pre

55 Extramedullary hematopoiesis (EMH) refers to the differe

56 Ineffective erythropoiesis and extramedullary hematopoiesis (EMH) regress, as reflected

57 ere anemia (2-4 g/dL), massive splenomegaly, extramedullary hematopoiesis (EMH), and hepatic iron ove

58 oplasms (MPNs), including varying degrees of extramedullary hematopoiesis (myeloid metaplasia) and sp

59 , an increase in splenic megakaryocytes, and extramedullary hematopoiesis accompany the hematologic c

60 e capacity is sustained by expanded sites of extramedullary hematopoiesis and is accompanied by multi

61 Mechanistically, FTY720 enhanced extramedullary hematopoiesis and massive accumulation of

62 thalassemia, with the potential of reversing extramedullary hematopoiesis and preventing splenectomy.

63 K hyperplasia, myelofibrosis, and consequent extramedullary hematopoiesis and splenomegaly.

64 2 heterozygous mutant mice exhibit increased extramedullary hematopoiesis and susceptibility to lymph

65 Dysmegakaryopoiesis and extramedullary hematopoiesis characterize primary myelof

66 rease in myeloid progenitor populations, and extramedullary hematopoiesis composed of maturing myeloi

67 der steady-state conditions and mobilize for extramedullary hematopoiesis during periods of stress su

68 aly, fibrotic and hypercellular bone marrow, extramedullary hematopoiesis in both spleen and liver, a

69 possibility of hemolytic anemia and splenic extramedullary hematopoiesis in Nrf2(-/-) mice.

70 We found that G6 significantly reduced extramedullary hematopoiesis in the liver and splenomega

71 mplicate IL-25-elicited MPP(type2) cells and extramedullary hematopoiesis in the promotion of Th2 cyt

72 Moreover, AEP deficiency provokes extramedullary hematopoiesis in the spleen and abnormall

73 erative phenotype, which was associated with extramedullary hematopoiesis in the spleen and liver, wa

74 lls; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver.

75 y high white blood cell counts and extensive extramedullary hematopoiesis in the spleen, liver, bone

76 one mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen.

77 tipotential progenitor cell mobilization and extramedullary hematopoiesis in the spleen.

78 marrow, and spleen; significantly increased extramedullary hematopoiesis in the spleen; and a 2-fold

79 Splenic extramedullary hematopoiesis is an integral component of

80 In the orthotopic BALB/cJ model, extramedullary hematopoiesis occurred in the spleen, res

81 However, KRAS activation enhanced extramedullary hematopoiesis of MA4-expressing cell line

82 it, leukocytosis, megakaryocyte hyperplasia, extramedullary hematopoiesis resulting in splenomegaly,

83 Extramedullary hematopoiesis was also evident, and granu

84 Increased extramedullary hematopoiesis was associated with elevate

85 ecrease in bone marrow hematopoiesis, active extramedullary hematopoiesis was observed in the spleen

86 Marked splenomegaly caused by extramedullary hematopoiesis was observed.

87 Greater HSPC mobilization and extramedullary hematopoiesis were reversed by raising HD

88 Instead, these animals exhibit extensive extramedullary hematopoiesis with progressive splenomega

89 e blood cells, bone marrow hypercellularity, extramedullary hematopoiesis, a tendency for thrombosis,

90 f Hmga2 enhanced megakaryopoiesis, increased extramedullary hematopoiesis, and accelerated the develo

91 enlargement of the spleen, increased splenic extramedullary hematopoiesis, and altered clinicopatholo

92 mune manifestations, including splenomegaly, extramedullary hematopoiesis, and autoantibody productio

93 loproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis a

94 acterized by erythrocytosis, granulocytosis, extramedullary hematopoiesis, and bone marrow fibrosis,

95 1(+) granulocytes, splenomegaly, evidence of extramedullary hematopoiesis, and bone marrow fibrosis,

96 enlarged spleen due to lymphoid hyperplasia, extramedullary hematopoiesis, and bone marrow hypoplasia

97 atopoietic stem and progenitor cell cycling, extramedullary hematopoiesis, and differentiation defect

98 gh incidence of premature death, age-related extramedullary hematopoiesis, and lack of early degenera

99 ymph nodes, splenomegaly due to erythrocytic extramedullary hematopoiesis, and lymphoid hyperplasia w

100 ave important implications for understanding extramedullary hematopoiesis, and may be relevant to cur

101 icrovesicular fatty metamorphosis, prolonged extramedullary hematopoiesis, and portal hypercellularit

102 poietic defects develop without compensatory extramedullary hematopoiesis, and the loss of HSCs occur

103 osis, resulting in extreme levels of splenic extramedullary hematopoiesis, anemia, and leukopenia.

104 gic malignancy characterized by BM fibrosis, extramedullary hematopoiesis, circulating CD34+ cells, s

105 e develop severe neutrophilia, splenomegaly, extramedullary hematopoiesis, decreased body weight, and

106 ient mice have a peripheral leukocytosis and extramedullary hematopoiesis, demonstrating that Lsc is

107 sease phenotype-bone marrow stromal changes, extramedullary hematopoiesis, ineffective erythropoiesis

108 d circulating MIP-1alpha and ameliorated the extramedullary hematopoiesis, inflammation, and osteopen

109 tipotential progenitor cell mobilization and extramedullary hematopoiesis, leading to decreased produ

110 , lead to autoinflammatory disease involving extramedullary hematopoiesis, skin and bone lesions.

111 by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic

112 opoietic stem cell function, contributing to extramedullary hematopoiesis, splenomegaly, BM failure,

113 n the P-loop of Gimap5, lymphopenia, hepatic extramedullary hematopoiesis, weight loss, and intestina

114 -old IRP1(-/-) mice exhibit splenomegaly and extramedullary hematopoiesis, which is corrected in olde

115 a dramatic increase in HSPC mobilization and extramedullary hematopoiesis.

116 a, they have macrocytic anemia and increased extramedullary hematopoiesis.

117 chitecture, bone marrow hypocellularity, and extramedullary hematopoiesis.

118 d splenomegaly with altered architecture and extramedullary hematopoiesis.

119 cture, and infected mice exhibited extensive extramedullary hematopoiesis.

120 Cs in the spleen, where we observed enhanced extramedullary hematopoiesis.

121 at was accompanied by splenomegaly caused by extramedullary hematopoiesis.

122 mph nodes were enlarged and exhibited marked extramedullary hematopoiesis.

123 fibrosis, osteosclerosis, angiogenesis, and extramedullary hematopoiesis.

124 with a recovery of medullary and decrease in extramedullary hematopoiesis.

125 ive hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis.

126 nto RBCs via formation of blood islands with extramedullary hematopoiesis.

127 tes, varying degrees of marrow fibrosis, and extramedullary hematopoiesis.

128 defect correlated with disease duration and extramedullary hematopoiesis.

129 rial infection, resulting in a transition to extramedullary hematopoiesis.

130 ls for growing in LEC-1 domains during liver extramedullary hematopoiesis.

131 hetic nervous system, expanded medullary and extramedullary hematopoiesis.

132 showed transient bone marrow depression and extramedullary hematopoiesis.

133 and a pathological reduction in red pulp and extramedullary hematopoiesis.

134 enitor cells in the bone marrow, and splenic extramedullary hematopoiesis.

135 R/Hedgehog-related genes in spleen, reducing extramedullary hematopoiesis.

136 rythroid differentiation and greatly reduced extramedullary hematopoiesis.

137 on in the splenic red pulp of typically rare extramedullary hematopoietic stem and progenitor cells,

138 expansion of macrophages, granulocytes, and extramedullary hematopoietic tissue.

139 ype I IFN signaling resulted in compensatory extramedullary hemopoiesis in the liver and spleen.

140 myeloid hyperplasia, and splenomegaly due to extramedullary hemopoiesis.

141 myeloid hyperplasia, and splenomegaly due to extramedullary hemopoiesis.

142 We also reported that extramedullary hepatic hematopoiesis occurs only in clos

143 ating factor (G-CSF), which was required for extramedullary HSC accumulation.

144 reased BAALC expression (P = .004), and less extramedullary involvement (P = .01).

145 MRD </= 1 x 10(-4) at weeks 5 and 12 and no extramedullary involvement or high-risk features.

146 romosome 13 deletion, advanced bone disease, extramedullary involvement, and patients with renal impa

147 tiple myeloma, pPCL presents more often with extramedullary involvement, anemia, thrombocytopenia, hy

148 D56 expression has been associated with both extramedullary leukemia and multidrug resistance, we sou

149 g the same hydrogels to a xenograft model of extramedullary leukemias, we confirm the pathological re

150 d to be associated with an increased risk of extramedullary leukemic involvement.

151 Extramedullary lympho-hematopoietic expansion was also o

152 We propose that inflammation-induced extramedullary lymphopoiesis represents a specialized me

153 nulocytic responses and consequently promote extramedullary lymphopoiesis.

154 Myeloid sarcoma is an extramedullary malignancy of myeloblasts.

155 d patients with intramedullary and extensive extramedullary manifestations of multiple myeloma underg

156 ated in 15, and blastic in 8 (7 medullary, 1 extramedullary); median time from transplantation to rel

157 , a defect in clot retraction, and increased extramedullary megakaryocytes.

158 stly, KO animals exhibited excessive splenic extramedullary megakaryocytopoiesis, which likely compen

159 hyperdiploid D1 group is virtually absent in extramedullary MM and MM cell lines, suggesting a partic

160 GUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines.

161 rves as the primary niche for hematopoiesis, extramedullary mobilization and differentiation of HSPCs

162 Our data implicate inflammation-induced extramedullary monocytopoiesis as a peripheral source of

163 tained need of newly made Mo was fostered by extramedullary monocytopoiesis in the spleen; d) splenic

164 Abrogation of extramedullary monocytopoiesis proved deleterious for in

165 megaly, myeloid bone marrow hyperplasia, and extramedullary myeloid cell infiltration of multiple org

166 th, but soon manifested marked medullary and extramedullary myeloid hyperplasia associated with cache

167 dependent expansion of functionally enhanced extramedullary myeloid progenitors that correlated with

168 revealed a partial loss of chromosome 6p in extramedullary myeloid sarcoma relapse of AML after sust

169 Extramedullary myeloma (EMM) is defined by the presence

170 R T cells led to resolution of medullary and extramedullary myeloma manifestations in a murine xenogr

171 on B cells or plasma cells, more than 90% of extramedullary myelomas (a late stage B-cell neoplasm) e

172 e 1 (VCAM-1)(+) macrophages are essential to extramedullary myelopoiesis because these macrophages us

173 3(+) T cells can negatively regulate splenic extramedullary myelopoiesis by suppressing the naive T c

174 e demonstrate that Kit(W-sh) causes aberrant extramedullary myelopoiesis characterized by the expansi

175 Extramedullary myelopoiesis occurs in peripheral organs

176 arrow myeloblasts and myelocytes, as well as extramedullary myelopoiesis.

177 ich FoxP3(+) regulatory T cells regulate the extramedullary myelopoiesis.

178 ults provide new insights into regulation of extramedullary myelopoiesis.

179 ar pathway that regulates myeloid bias in an extramedullary niche.

180 Monocytes born in such extramedullary niches intravasate, circulate, and accumu

181 ssociated with worse prognosis than isolated extramedullary or late relapse (> 30 months from diagnos

182 ant tumor proliferation and dissemination to extramedullary organs, leading to disease progression an

183 , reduced fitness, short t1/2, and potential extramedullary origin.

184 These findings provide a unique model of extramedullary PCT for studies on pathogenesis and treat

185 A subset of PCT, designated extramedullary PCT, is distinguished from multiple myelo

186 solitary bone plasmacytoma (SBP; n = 35) and extramedullary plasmacytoma (EMP; n = 29) through multip

187 ic insult, these cells are replenished by an extramedullary radio-resistant and UV-sensitive Bmi1(+)

188 and less likely to have combined marrow and extramedullary relapse (19% versus 30%).

189 8 patients transplanted in CR2 for isolated extramedullary relapse (all MRD-), MRD was detected at h

190 erall survival of patients who experience an extramedullary relapse is <6 months.

191 with B-precursor ALL, in first marrow and/or extramedullary relapse were eligible.

192 We use both systemic and local treatment for extramedullary relapse, mainly represented by radiothera

193 posed to marrow involvement only or isolated extramedullary relapse, was associated with impaired out

194 p (P < .0001), showing the largest effect on extramedullary relapses.

195 bone marrow B lineage cells is dependent on extramedullary signals.

196 eukemic blasts in blood, bone marrow, or any extramedullary site after 4 to 6 weeks of remission-indu

197 for early versus late relapse, marrow versus extramedullary site, adolescent versus younger age and T

198 Ns, and positions the spleen as an important extramedullary site, which can continuously supply growi

199 were lost from the BM due to mobilization to extramedullary sites and differentiation.

200 ematopoiesis in marrow, and hematopoiesis in extramedullary sites and is associated with abnormal meg

201 ection work-up revealing increased uptake at extramedullary sites and/or bones and joints that would

202 duced primarily through the establishment of extramedullary sites of eosinophilopoiesis.

203 igh sensitivity and specificity, and detects extramedullary sites of proliferating clonal plasma cell

204 as decreased in bone marrow and increased in extramedullary sites of Prx1-Cre;Has2(flox/flox);Has1(-/

205 occurring not only in the marrow but also in extramedullary sites such as the spleen.

206 Our findings indicate that extramedullary sites supplement the hematopoietic functi

207 tic plasma cells in the bone marrow or other extramedullary sites, along with evidence of disease-rel

208 in the skeleton significantly differed from extramedullary sites, showing similar numbers but differ

209 cking to the bone marrow, the skin and other extramedullary sites.

210 emination of tumor to other bones but not to extramedullary sites.

211 onment for establishment of hematopoiesis in extramedullary sites.

212 t and unlike PCs, are primarily localized at extramedullary sites.

213 ively in marrow, and subsequent reseeding of extramedullary sites.

214 onstrated a role for ST6Gal-1, possibly from extramedullary sources (eg, produced in liver) in regula

215 mours can be divided into intramedullary and extramedullary spinal-cord tumours on the basis of their

216 bers of primitive hematopoietic cells in the extramedullary spleen site.

217 In phenylhydrazine-treated Lyn-/- mice, extramedullary splenic erythropoiesis was hyperactivated

218 /-), and PU.1(+/-) Spi-B(-/-) mice displayed extramedullary splenic hematopoiesis.

219 CD26 expression may explain the abnormal extramedullary spread of CML LSC, and inhibition of CD26

220 contributing to malignant expansion and the extramedullary spread of leukemic SC (LSC) in CML.

221 esses within the bone marrow, and then to an extramedullary stage from which MM cell lines are genera

222 vironment until progressing to very advanced extramedullary stages of the disease such as plasma cell

223 epended on S1P(1) signaling, and allowed the extramedullary tissue to supply new tumor-associated mac

224 Migratory HSPCs proliferate within extramedullary tissues and give rise to tissue-resident

225 egulate hematopoietic stem cell migration to extramedullary tissues and the metastasis of cancer stem

226 HSPC egress from extramedullary tissues into lymph depends on sphingosine

227 The frequency of extramedullary toxicities was comparable.

228 retazine has significant activity and modest extramedullary toxicity in elderly patients with AML or

229 In these nine patients, extramedullary toxicity was absent, neutropenia did not

230 No significant extramedullary toxicity was seen.

231 es of MK-0457 associated with no significant extramedullary toxicity, is very encouraging.

232 2 per course were administered without major extramedullary toxicity.

233 se, frequency at relapse, and progression to extramedullary tumor.

234 In patients with NF2 and spinal tumors, extramedullary tumors (predominantly NSTs) were present

235 h intramedullary tumors versus 16 (59%) with extramedullary tumors had undergone surgery for the resp

236 Intramedullary and intradural extramedullary tumors were counted, and imaging features

237 tramedullary tumors, 27 (55%) had intradural extramedullary tumors, and 22 (45%) had at least one tum

238 This phenotype manifested further with extramedullary tumors, hepatic macrophage infiltration,

239 Extramedullary uptake also occurred in 6 (23%) of 26 pat

240 This extramedullary uptake was a very poor prognostic factor